INGN Stock Recent News
INGN LATEST HEADLINES
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Inogen's price performance has been poor this year, but a closer look at the numbers suggests that the market's negativity may be unwarranted. Management is actively taking steps to address the company's issues. I'm issuing a Buy rating, but suggest holding Inogen in a well-diversified portfolio more so than as a single issue.
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following investor conferences: Stifel 2023 Healthcare Conference on Wednesday, November 15 at 10:20 a.m. Eastern Time Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29 at 10:30 a.m. Eastern Time A live webcast and archived recording of each presentation wil.
Despite higher international business-to-business sales and rental revenues, Inogen's (INGN) overall third-quarter results reflect soft performances.
Inogen, Inc. (NASDAQ:INGN ) Q3 2023 Results Conference Call November 7, 2023 5:00 PM ET Company Participants Marissa Bych - IR Gilmartin Group Nabil Shabshab - President and CEO Mike Sergesketter - Interim CFO Conference Call Participants Colin Clark - Stifel Margaret Kaczor - William Blair Rohin Patel - JPMorgan Mike Matson - Needham & Company Operator Greetings, and welcome to the Inogen 2023 Third Quarter Financial Results Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded.
Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.
Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.